Bromide

Bromide

SCHEMBL1731508

Br.CCc1ccc2c(n1)C(=N)N(CC(=O)c1cc(CNCCC(=O)O)c(O)c(C(C)(C)C)c1)C2

nearest known ligand 0.36

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ACHE known ✓ P22303 1/20 0.31
F2R P25116 15/20 0.33
CYP3A4 P08684 2/20 0.32
BCHE P06276 1/20 0.31
MAOA P21397 1/20 0.31
MAOB P27338 1/20 0.31
KDM4E B2RXH2 1/20 0.31
MAPT P10636 1/20 0.31
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL5484963 0.94 F2R (0.34) F2RBCHEMAOAACHEMAOB
SCHEMBL27552972 0.92 F2R (0.33) F2RCYP3A4BCHEMAOAACHE
Bromide SCHEMBL1729691 0.87 F2R (0.32) F2R
Bromide SCHEMBL1730897 0.87 F2R (0.42) F2RKDM4EMAPTRAB9ASMN1; SMN2
SCHEMBL14449085 0.86 F2R (0.43) F2RCYP3A4KDM4EMAPTRAB9A
Bromide SCHEMBL1731367 0.83 F2R (0.37) F2RKDM4EMAPTRAB9ASMN1; SMN2
Bromide SCHEMBL1730092 0.83 F2R (0.37) F2RKDM4EMAPTRAB9A
Bromide SCHEMBL1732121 0.83 F2R (0.33) F2R
Bromide SCHEMBL5488061 0.83 F2R (0.36) F2RKDM4EMAPTRAB9A
Bromide SCHEMBL1731726 0.83 KDM4E (0.34) F2RKDM4EMAPTRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1391451-B1 2-IMINOPYRROLIDINE DERIVATES EISAI R&D MAN CO LTD (JP) 2011-11-23 EP disclosed
US-7244730-B2 2-iminopyrrolidine derivatives EISAI CO., LTD (JP) 2007-07-17 US disclosed
US-20050245592-A1 2-Iminopyrrolidine derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-11-03 US disclosed
US-20050004204-A1 2-Iminopyrrolidine derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245592-A1 2-Iminopyrrolidine derivatives H1-2, H1-3, H1-0 ACHE 2759/4885F2R 2290/4885CYP3A4 506/4885
US-20050004204-A1 2-Iminopyrrolidine derivatives H1-2, H1-3, H1-0 ACHE 2748/4885F2R 2289/4885CYP3A4 501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.